Application Note

Analytical Procedure Development Following ICH Q14: An AQbD Approach

GettyImages-1487365250 Clinical Analytics

With the adoption of ICH Q14 in November 2023, the landscape of analytical method development has evolved, introducing a more structured and science-driven framework that aligns with the principles of Analytical Quality by Design (AQbD). Explore how ICH Q14 guidance provides clarity on analytical procedure development, an area previously underserved by regulatory standards, and enables both minimal and enhanced approaches to method creation.

At the core of the enhanced approach is the Analytical Target Profile (ATP), which defines method performance criteria upfront, guiding method selection, parameter risk assessment, and design of experiments (DoE).With a comprehensive workflow that incorporates testing, forced degradation studies, and risk-based control strategies early in development, this approach leads to more efficient validation and a reduced regulatory burden later in the product lifecycle. By embracing the AQbD methodology, organizations can achieve more resilient, adaptable, and compliant analytical procedures. Discover how Labcorp's ICH Q14-compliant approach can improve your analytical outcomes.

access the Application Note!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Outsourced Pharma

Labcorp Biopharmaceutical CMC Services